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Periodontal disease is accompanied by inflammation of the gingiva and destruction of periodontal tissues, leading to alveolar bone




) and cytokines such as interleukin- (IL-)6 and IL-8
have been known to play important roles in inflammatory responses and tissue degradation. In the present study, we investigated




), IL-6, and IL-8 by human gingival
fibroblasts (HGFs) treated with lipopolysaccharide (LPS) from Porphyromonas gingivalis. Kakkonto concentration dependently
suppressed LPS-induced PGE
2
production but did not alter basal PGE
2
levels. In contrast, kakkonto significantly increased LPS-
induced IL-6 and IL-8 production. Kakkonto decreased cyclooxygenase- (COX-)1 activity to approximately 70% at 1mg/mL but




), annexin1, or LPS-induced COX-2
expression. Kakkonto suppressed LPS-induced extracellular signal-regulated kinase (ERK) phosphorylation, which is known to
lead to ERK activation and cPLA
2
phosphorylation. These results suggest that kakkonto decreased PGE
2
production by inhibition
of ERK phosphorylation which leads to inhibition of cPLA
2
phosphorylation and its activation.Therefore, kakkonto may be useful
to improve gingival inflammation in periodontal disease.
1. Introduction
Periodontal disease is accompanied by inflammation of the
gingiva and destruction of periodontal tissues, leading to




), interleukin- (IL-)6, and IL-8 are known to play
important roles in inflammatory responses and tissue degra-
dation. PGE
2
has several functions in vasodilation, the
enhancement of vascular permeability and pain, and the
induction of osteoclastogenesis and is believed to play impor-
tant roles in inflammatory responses and alveolar bone
resorption in periodontal disease [1]. IL-6 has the ability
to induce osteoclastogenesis [2, 3]. IL-8 acts as a chemoat-
tractant for neutrophils [4] that produce proteases such as
cathepsin, elastase, and matrix metalloproteinase- (MMP-)8,
leading to tissue degradation.
Recently, we reported that several kampo medicines,
shosaikoto [5], hangeshashinto [6], and orento [7], sup-
press lipopolysaccharide- (LPS-) induced PGE
2
production
by HGFs and suggested that these kampo medicines have
anti-inflammatory effects in periodontal disease. Another
kampomedicine, kakkonto (TJ-1), has been clinically used for
various diseases such as the common cold, coryza, the initial
stage of febrile diseases, and inflammatory diseases. There
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Kakkon Puerariae Radix 4.0 0.111
Taiso Zizyphi Fructus 3.0 0.083
Mao Ephedrae Herba 3.0 0.083
Kanzo Glycyrrhizae Radix 2.0 0.056
Keihi Cinnamomi Cortex 2.0 0.056
Shakuyaku Paeoniae Radix 2.0 0.056
Shokyo Zingiberis Rhizoma 2.0 0.056
Total 18.0 0.500
∗7.5 g of kakkonto product contains 3.75 g of a dried extract of the mixed
crude drugs.
are several reports that kakkonto shows antiallergic effects
[8, 9] and antiviral effects [10–13] in animal and in vitro exper-
imental models. For anti-inflammatory effects, kakkonto has
been reported to decrease PGE
2
production in cultured
rabbit astrocytes [14]. Therefore, we considered the possi-
bility that kakkonto decreases PGE
2
production by human
gingival fibroblasts (HGFs) and has anti-inflammatory effects
with respect to periodontal disease. However, the anti-
inflammatory effects of kakkonto are not adequately under-
stood.
HGFs are the most prominent cells in periodontal tissue.
Moreover, LPS-treated HGFs produce inflammatory chemi-
cal mediators such as PGE
2
and inflammatory cytokines such
as IL-6 and IL-8 [2, 15, 16]. Moreover, because HGFs have
sustained production of PGE
2
[17], IL-6, and IL-8 [18] in the
presence of LPS, these mediators and cytokines in periodon-
tal tissues are thought to be derived from HGFs. Therefore,
we believe that examining the effects of drugs on HGFs,
as well as on monocytes and macrophages, is important in
the study of periodontal disease. In the present study, we
examined the effect of kakkonto on LPS-induced PGE
2
, IL-
6, and IL-8 production using this in vitromodel.
2. Materials and Methods
2.1. Reagents. Kakkonto was purchased from Tsumura & Co.
(Tokyo, Japan; lot number: D23122), and its components are
listed in Table 1. Kakkonto was suspended in Dulbecco’s
modified Eagle’s medium (D-MEM, Sigma, St. Louis, MO,
USA) containing 10% heat-inactivated fetal calf serum, 100
units/mL penicillin, and 100mg/mL streptomycin (culture
medium) and was rotated at 4∘C overnight. Then, the sus-
pension was centrifuged and the supernatant was filtrated
through a 0.45 𝜇m-pore membrane. Phorbol 12-myristate 13-
acetate (PMA) purchased from Sigma. Other reagents were
purchased from Nacalai tesque (Kyoto, Japan). LPS from
Porphyromonas gingivalis 381 was provided by Professor
Nobuhiro Hanada (School of Dental Medicine, Tsurumi
University, Japan).
2.2. Cells. HGFs were prepared as described previously [6].
In brief, HGFs were prepared from free gingiva during the
extraction of an impacted tooth with the informed consent
of the subjects who consulted Matsumoto Dental University
Hospital. The free gingival tissues were cut into pieces and
seeded onto 24-well plates (AGC Techno Glass Co., Chiba,
Japan). HGFs were maintained in culture medium at 37∘C in
a humidified atmosphere of 5% CO. For passage, HGFs were
trypsinized, suspended, and plated into new cultures in a 1 : 3
dilution ratio. HGFs were used between the 10th and 15th
passages in the assays.This study was approved by the Ethical
Committee of Matsumoto Dental University (number 0063).
2.3. Cell Viability. The numbers of cells were measured
using WST-8 (Cell Counting Kit-8; Dojindo, Kumamoto,
Japan) according to the manufacturer’s instructions. In brief,
HGFs (10,000 cells/well) were seeded in 96-well plates (AGC
Techno Glass Co., Chiba, Japan) and incubated in serum-
containing medium at 37∘C overnight. Then, the cells were
treatedwith various concentrations of kakkonto (0, 0.5, 1, 2, 5,
and 10mg/mL) in the absence or presence of LPS (10 ng/mL)
for 24 h (200𝜇L each well) in quadruplicate for each sample.
Then, the media were removed by aspiration and the cells
were treated with 100 𝜇L of mixture of WST-8 with culture
medium for 2 h at 37∘C in CO incubator. Optical density
wasmeasured (measuredwavelength at 450 nmand reference
wavelength at 655 nm) using an iMark microplate reader
(Bio-Rad, Hercules, CA, USA), and the mean background
value was subtracted from each value. Data is represented as
means ± SD (𝑛 = 4).
2.4. Enzyme-Linked Immunosorbent Assay (ELISA). HGFs
(10,000 cells/well) were seeded in 96-well plates and incu-
bated in serum-containing medium at 37∘C overnight. Then,
the cells were treatedwith various concentrations of kakkonto
(0, 0.01, 0.03, 0.1, 0.3, and 1mg/mL) in the absence or presence
of LPS (10 ng/mL) for 24 h (200𝜇L each well) in triplicate for
each sample. After the culture supernatants were collected,
viable cell numbers weremeasured usingWST-8 as described
above. The concentrations of PGE
2
, IL-6, and IL-8 in the
culture supernatants were measured by ELISA according to
the manufacturer’s instructions (PGE
2
, Cayman Chemical,
Ann Arbor, MI, USA; IL-6 and IL-8, Biosource International
Inc., Camarillo, CA, USA) and were adjusted by the number
of viable cells. Data are represented as ng or pg per 10,000 cells
(mean ± SD, 𝑛 = 3).
2.5. Cyclooxygenase Activity. The effects of kakkonto on
the activities of cyclooxygenase (COX)-1 and COX-2 were
analyzed using a COX inhibitor screening assay kit (Cayman
Chemical, Ann Arbor, MI, USA) according to the manu-
facturer’s instructions. COX activities were evaluated by the
measurement of prostaglandin produced from arachidonic
acid by COX-1 or COX-2. These values were normalized to
a relative value of 100% for cells without LPS or kakkonto
treatments, and are represented as means ± SD (𝑛 = 3).
2.6. Western Blotting. HGFs were cultured in 60mm dishes
and treated with combinations of LPS and kakkonto for
the indicated times. Then, cells were washed twice with
Tris-buffered saline, transferred into microcentrifuge tubes,
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Figure 1: Effects of kakkonto on HGFs viability. The effect of
kakkonto on the viability of HGFs at 24 h. HGFs were plated in
96-well microplates at 10,000 cells/mL, and media containing LPS
and kakkonto were added. Cell numbers were evaluated by WST-
8 at 24 h. The optical density (OD) was normalized to a relative
value of 100% for cells without LPS or kakkonto treatments and
is represented as means ± SD (𝑛 = 4). Open circles, treatment
without LPS; closed circles, treatment with 10 ng/mL of LPS. ∗∗𝑃 <
0.01 and ∗∗∗𝑃 < 0.001 (without kakkonto versus with kakkonto
in the absence of LPS). #𝑃 < 0.01 and ##𝑃 < 0.001 (without
kakkonto versus with kakkonto in the presence of LPS). 𝑃 values
were calculated by pairwise comparisons and corrected with the
Holm method (16 null hypotheses).
and centrifuged at 6,000×g for 5min at 4∘C. Supernatants
were aspirated and cells were lysed on ice in lysis buffer
(50mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium
deoxycholate, 150mM NaCl, 1mM ethyleneglycol bis(2-
aminoethylether) tetraacetic acid (EGTA), 1mM sodium
orthovanadate, 10mM sodium fluoride, 1mMphenylmethyl-
sulfonyl fluoride, 10 𝜇g/mL aprotinin, 5 𝜇g/mL leupeptin, and
1 𝜇g/mLpepstatin) for 30min at 4∘C.Then, sampleswere cen-
trifuged at 12,000×gfor 15min at 4∘C, and supernatants were
collected. The protein concentration was measured using a
BCA Protein Assay Reagent Kit (Pierce Chemical Co., Rock-
ford, IL, USA).
The samples (10 𝜇g of protein) were fractionated in a
polyacrylamide gel under reducing conditions and trans-
ferred onto a polyvinylidene difluoride (PVDF) membrane
(Hybond-P; GE Healthcare, Uppsala, Sweden). The mem-
branes were blocked with 5% ovalbumin for 1 h at room
temperature and incubated with primary antibody for an
additional 1 h. The membranes were further incubated with
horseradish peroxidase-conjugated secondary antibodies for
1 h at room temperature. Protein bands were visualized with
an ECL Kit (GE Healthcare).





, sc-438, 1 : 200 dilution),
annexin1 (sc-11387, 1 : 1,000 dilution), and actin (sc-1616,
1 : 1,000 dilution), which detects a broad range of actin
isoforms, were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against extracellular
signal-regulated kinase (ERK; p44/42 MAP kinase antibody,
1 : 1,000 dilution) and phosphorylated ERK (Phospho-p44/42
MAPK (Thr202/Tyr204) (E10)monoclonal antibody, 1 : 2,000
dilution) were from Cell Signaling Technology (Danvers,
MA,USA).Horseradish peroxidase-conjugated anti-goat IgG
(sc-2020, 1 : 20,000 dilution) was from Santa Cruz, and anti-
rabbit IgG (1 : 20,000 dilution) and anti-mouse IgG (1 : 20,000
dilution) were from DakoCytomation (Glostrup, Denmark).
2.7. Statistical Analysis. Differences between groups were
evaluated by the two-tailed pairwise comparison test with
a pooled variance, followed by correction with the Holm
method (total 16 null hypotheses; 5 null hypotheses without
kakkonto versus with kakkonto in the absence of LPS, 5 null
hypotheses without kakkonto versus with kakkonto in the
presence of LPS, and 6 null hypotheses without LPS versus
with LPS) (Figures 1 and 2). Differences between the control
group and experimental groups were evaluated by a two-
tailed Dunnett’s test (Figure 3).
All computations were performedwith the statistical pro-
gram R (http://www.r-project.org/). Dunnett’s test was per-
formed using the “glht” function in the “multcomp” package.
Values with 𝑃 < 0.05 were considered significantly different.
3. Results
3.1. Effects of Kakkonto on HGFs Viability. First, we examined
the effect of kakkonto on HGFs viability. The viability of
HGFs was approximately 90% at up to 1mg/mL of kakkonto
for a 24 h treatment in the absence or presence of LPS
(Figure 1).The viabilities were approximately 70% and 20% at
5mg/mL and 10mg/mL of kakkonto, respectively (Figure 1).
Therefore, we used kakkonto at the concentrations of up to
1mg/mL in further experiments.
3.2. Effects of Kakkonto on PGE
2
, IL-6, and IL-8 Production.
We examined whether kakkonto affects the production of
PGE
2
and inflammatory cytokines (IL-6 and IL-8) by HGFs.
Because kakkonto affects cell viability, the concentrations of
PGE
2
, IL-6, and IL-8 needed to be adjusted according to
viable cell number.
When HGFs were treated with 10 ng/mL of LPS, HGFs
produced large amounts of PGE
2
, IL-6, and IL-8. Indometh-
acin decreased LPS-induced PGE
2
production in a concen-
tration-dependent manner but slightly decreased LPS-
induced IL-6 and IL-8 production (data not shown).
Kakkonto significantly decreased PGE
2
production in a con-
centration-dependent manner (Figure 2(a)). In the absence
of LPS, kakkonto had no effect on PGE
2
production (Fig-
ure 2(a)). In contrast, kakkonto increased LPS-induced IL-6
and IL-8 production (Figures 2(b) and 2(c)). In the absence of
LPS, up to 0.1mg/mL of kakkonto did not affect IL-6 and IL-
8 production, but above 0.3mg/mL of kakkonto, their con-
centrations were increased (Figures 2(b) and 2(c)). Similar
results were obtained using human skin fibroblast TIG-103
cells (data not shown).
3.3. Effects of Kakkonto on COX Activities. Because PGE
2
production is regulated by COX enzymes and suppressed
by acid NSAIDs such as aspirin and diclofenac sodium,
which inhibit COXactivities, we examinedwhether kakkonto
inhibits COX-1 and COX-2 activities. Kakkonto decreased
4 ISRN Pharmacology


















































































Figure 2: Effects of kakkonto on the production of PGE
2
, IL-6, and IL-8. HGFs were treated with combinations of LPS (0 and 10 ng/mL) and
kakkonto (0, 0.01, 0.3, 0.1, 0.3, and 1mg/mL) for 24 h. Concentrations of PGE
2
(a), IL-6 (b), and IL-8 (c) were measured by ELISA, adjusted
by cell number, and expressed as per 10,000 cells (mean ± SD, 𝑛 = 3). Open circles, treatment without LPS; closed circles, treatment with
10 ng/mL of LPS. ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001 (without kakkonto versus with kakkonto). ##𝑃 < 0.001 (without LPS versus with LPS). 𝑃
values were calculated by pairwise comparisons and corrected with the Holm method (16 null hypotheses).







































Figure 3: Effects of kakkonto on COX activities. COX activities were evaluated bymeasurement of prostaglandin produced from arachidonic
acid by COX-1 or COX-2. These values were normalized to a relative value of 100% for cells without LPS or kakkonto treatments and are
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Figure 4: Effects of kakkonto on cPLA
2
, COX-2, and annexin1
expressions. HGFs were treated with a combination of LPS (0 or
10 ng/mL) and kakkonto (0, 0.01, or 1mg/mL) for 8 h, and protein
levels were examined by western blotting.
COX-1 activity to approximately 70% at 1mg/mL but did not
affect COX-2 activity (Figure 3).
3.4. Effects of Kakkonto onMolecular Expression in the Arachi-
donic Acid Cascade. We examined whether kakkonto affects
the expression of molecules in the arachidonic acid cascade.
cPLA
2
is the most upstream enzyme in the arachidonic
acid cascade and releases arachidonic acid from plasma
membranes. Kakkonto did not alter cPLA
2
expression in
the absence or presence of LPS (Figure 4). COX-2 was not
detected in the absence of LPS. Treatment with kakkonto
alone increased COX-2 expression. However, kakkonto
did not alter LPS-induced COX-2 expression (Figure 4).
Annexin1, also named lipocortin1, is an anti-inflammatory
mediator produced by glucocorticoids that inhibit cPLA
2
activity [19, 20]. However, neither LPS nor kakkonto showed
an effect on annexin1 expression (Figure 4).
3.5. Effects of Kakkonto on ERK Phosphorylation. cPLA
2
is
reported to be directly phosphorylated at Ser505 by ERK,
resulting in cPLA
2
activation [21, 22].Therefore, we examined
whether kakkonto suppresses LPS-induced ERK phospho-
rylation. ERK phosphorylation was enhanced at 0.5 h after
LPS treatment and thereafter was attenuated. Onemg/mL of
kakkonto suppressed LPS-induced ERK phosphorylation at
0.5 h to 2 h (Figure 5).
4. Discussion
In the present study, we examined the effect of kakkonto
on LPS-induced PGE
2
, IL-6, and IL-8 production by
HGFs. Kakkonto concentration dependently decreased LPS-
induced PGE
2
production but did not affect PGE
2
produc-
tion without LPS treatment, similar to shosaikoto, hange-
shashinto, and orento [5–7]. Moreover, kakkonto suppressed
LPS-induced ERK phosphorylation. In contrast, kakkonto
increased LPS-induced IL-6 and IL-8 production. It is widely
known that PGE
2
leads to inflammatory responses such
pERK






Figure 5: Effects of kakkonto on LPS-induced ERK phosphoryla-
tion. HGFs were untreated (0 h), treated with LPS (10 ng/mL), or
treated with both LPS and kakkonto (1mg/mL) for 0.5, 1, and 2 h.
As a positive control, HGFs were treated with 1 𝜇M of PMA for
0.5 h. Western blotting was performed using antiphosphorylated
ERK or anti-ERK antibodies. pERK: phosphorylated ERK. Upper
band indicates ERK1 (p44 MAPK) and lower band indicates ERK2
(p42 MAPK).
as vasodilation, enhanced vascular permeability, and pain
generation [1]. Acid non-steroidal anti-inflammatory drugs
NSAIDs show anti-inflammatory effects by suppression of
PGE
2
production, even though they do not affect IL-6 and IL-
8 production. Our findings showing that kakkonto decreases
LPS-induced PGE
2
production suggest that kakkonto also
has anti-inflammatory effects in periodontal disease and that
its effects are mainly mediated by suppression of PGE
2
production even though kakkonto increased LPS-induced IL-
6 and IL-8 production.
Our results showed that kakkonto suppressed LPS-
induced ERK phosphorylation in HGFs. Previously, we
demonstrated that orento inhibits LPS-induced ERK phos-
phorylation and cPLA
2
activation, leading to the suppression
of PGE
2
production in HGFs [7]. Therefore, we consider that
kakkonto decreased LPS-induced PGE
2
production through
the suppression of ERK phosphorylation in HGFs.
Although kakkonto increased COX-2 expression in the
absence of LPS, kakkonto did not alter PGE
2
production. We
consider a likely reason to be the suppression of cPLA
2
acti-
vation through the inhibition of ERKphosphorylation and/or
the suppression of COX-1 activity. However, the components
that induce COX-2 expression remain unknown.
Our results showed that kakkonto increased LPS-induced
IL-6 and IL-8 production by HGFs. Previously, we reported
that the activation of the protein kinase A (PKA) pathway
by adrenaline or aminophylline increases LPS-induced IL-
6 and IL-8 production in HGFs [23] and that H-89, a PKA
inhibitor, decreases LPS-induced IL-6 and IL-8 production
[23, 24]. Therefore, kakkonto may activate the PKA pathway.
In general, steroidal anti-inflammatory drugs (SAIDs)
suppress the expression of cPLA
2
, COX-2, and inflammatory
cytokines (such as IL-6 and IL-8) and induce the expression of
annexin1. However, kakkonto did not affect cPLA
2
, annexin1,
or LPS-induced COX-2 expression, and it increased IL-6 and
6 ISRN Pharmacology
IL-8 production. This therefore suggests that the mechanism
by which kakkonto decreases PGE
2
production is different
from that of SAIDs.
Many studies have demonstrated thatNSAIDadministra-
tion prevents gingival inflammation [25] and several clinical
studies have indicated that the concentration of PGE
2
in
gingival crevicular fluid (GCF) is increased in periodontal
disease [26] and is decreased by oral administration or
mouthwash with NSAIDs [27, 28]. Considering that both
NSAIDs and kakkonto suppress PGE
2
production, it is
possible that administration of kakkonto also decreases the
PGE
2
concentration in GCF and results in the improvement
of gingival inflammation. Therefore, kakkonto may be useful
for the improvement of gingival inflammation in periodon-
tal disease. Importantly, kakkonto did not affect the basal
level of PGE
2
, although kakkonto decreased COX-1 activity
to approximately 70%. Because PGE
2
produced by COX-1
protects gastric mucosa, these results suggest that kakkonto
may cause minimal gastrointestinal dysfunction.
5. Conclusion
We demonstrated that kakkonto suppresses LPS-induced
ERK phosphorylation, resulting in the suppression cPLA
2
activation and further PGE
2
production by HGFs. These
results suggest that kakkonto is clinically useful for the
improvement of inflammatory responses in periodontal dis-
ease.
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